文献速递类风湿关节炎

接受生物制剂改善病情抗风湿药治疗的类风湿关节炎患者第二原发恶性肿瘤风险与死亡率:一项丹麦人群队列研究

Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study.
PubMed 文献 · Ann Rheum Dis · 2017-12-07

在DANBIO登记2000-2011年15 286例类风湿关节炎患者中,1678例有原发癌症史;曾用生物制剂改善病情抗风湿药(bDMARD)者发生第二原发恶性肿瘤(SMN)的HR为1.11(95%CI 0.74-1.67),与未用者相比无显著升高;死亡率方面结论不明确。

要点

  • 有癌症史的类风湿关节炎患者中,bDMARD使用与SMN风险无显著增加相关(HR 1.11,95%CI 0.74-1.67)。
  • 原发癌症诊断前使用bDMARD者死亡HR为1.53(95%CI 1.13-2.09),进一步校正原发癌症范围后为1.20(95%CI 0.88-1.63)。
  • bDMARD治疗患者的死亡率无法得出明确结论。

核心结论

  • 在有癌症史的类风湿关节炎患者中,bDMARD治疗与SMN风险增加无关。
  • 关于bDMARD治疗的类风湿关节炎患者死亡率,无法得出明确结论。

研究设计与样本

  • 丹麦人群队列研究,基于DANBIO登记2000-2011年15 286例类风湿关节炎患者,其中1678例根据丹麦癌症登记有原发癌症诊断。
  • 计算SMN和死亡的HR,随访期间bDMARD使用状态分为原发癌症诊断前使用、仅诊断后使用、诊断前后均使用及未使用。

主要发现

  • 随访期间,279例类风湿关节炎患者在原发癌症诊断前有bDMARD使用的人年,220例仅在诊断后有使用,92例诊断前后均有使用,1203例贡献未使用分层。
  • 与未使用相比,曾用bDMARD者发生SMN的HR为1.11(95%CI 0.74-1.67,按癌症部位校正)。
  • 原发癌症诊断前使用bDMARD者死亡HR为1.53(95%CI 1.13-2.09)。
  • 进一步校正原发癌症范围后,原发癌症诊断前使用bDMARD者死亡HR为1.20(95%CI 0.88-1.63),仅癌症后使用者为1.36(95%CI 0.78-2.39),癌症前后均使用者为1.22(95%CI 0.70-2.13)。

关键数值与推荐

  • SMN风险:曾用bDMARD vs 未使用,HR 1.11(95%CI 0.74-1.67,按癌症部位校正)。
  • 死亡风险(未校正原发癌症范围):原发癌症诊断前使用bDMARD,HR 1.53(95%CI 1.13-2.09)。
  • 死亡风险(校正原发癌症范围后):诊断前使用HR 1.20(95%CI 0.88-1.63),仅诊断后使用HR 1.36(95%CI 0.78-2.39),诊断前后均使用HR 1.22(95%CI 0.70-2.13)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the risk of a second malignant neoplasm (SMN) and mortality in patients with rheumatoid arthritis (RA) with a history of a primary cancer diagnosis and treated with biological disease-modifying antirheumatic drugs (bDMARD). METHODS: Among patients with RA (n=15 286) registered in the DANBIO Register during 2000-2011, 1678 had a primary cancer according to the Danish Cancer Registry. HRs for SMN and death were calculated. RESULTS: During follow-up there were 279 patients with RA contributing person-years to the bDMARDs use before their primary cancer diagnosis, 220 to the only after, 92 to the both before and after, while 1203 patients with RA contributed to the non-use strata. Ever use of bDMARDs was associated with a HR of 1.11 (95% CI 0.74 to 1.67) for developing a SMN compared with non-use (cancer site adjusted). The HR for death associated with bDMARD use before the primary cancer diagnosis was increased 1.53 (95% CI 1.13 to 2.09). After further adjustment for extent of the primary cancer, the HR for death was 1.20 (95% CI 0.88 to 1.63) for bDMARDs use before cancer, 1.36 (95% CI 0.78 to 2.39) for bDMARD use only after cancer and 1.22 (95% CI 0.70 to 2.13) for use both before and after the cancer. CONCLUSIONS: Among patients with RA with a history of cancer, treatment with bDMARDs was not associated with increased risk of SMN. No clear conclusion can be drawn regarding mortality in bDMARD-treated patients with RA.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Dreyer L, Cordtz RL, Hansen IMJ, et al. Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study. Ann Rheum Dis. 2017. PMID: 29217620. doi:10.1136/annrheumdis-2017-212086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。